Log in to search using one of your social media accounts:

 

FDA OKs First Adjuvant Treatment for Kidney Cancer FDA OKs First Adjuvant Treatment for Kidney Cancer
Sunitinib is now approved for use after surgery in renal cell carcinoma patients who are at high risk for disease recurrence.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA expands approval for Pfizer cancer drug Sutent
(Reuters) - The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approval of Sutent to reduce the risk of kidney cancer returning
FDA approves first adjuvant treatment for adult patients who are at a high risk of kidney cancer returning after a kidney has been removed. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2017 Category: American Health Source Type: news

Pfizer receives FDA approval for SUTENT ® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

It Takes All of Us ” Casino Royale - Kidney Cancer Awareness Gala
The Dennis C. Baylor“BIG LUV” Kidney Cancer Foundation is proud to Announce that we will be hosting an elegant Evening with a purpose.Theme:“It Takes All of Us” Casino Royale - Kidney Cancer Awareness Gala to beheld:Friday November 24, 2017 at The Venue located at 10 Tallmadge Circle,Tallmadge OH 44278 - 8:00pm-1:00am This“Orange is The New Black” Semi-Formal event will feature Open Bar,Silent and Live auctions, Chef/Staff and entertainment. Guests will see a video tribute in memory of Dennis Baylor as well as hear inspirational storiesfrom kidney patients, caregivers, kidney d...
Source: Kidney Cancer Association - October 31, 2017 Category: Urology & Nephrology Source Type: news

Request for Proposals (RFP): Kidney Cancer Young Investigator Award (YIA)
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017. The YIA is a one-year research grant totaling $50,000, which is paid in two equal installments to the awardee’s institution. Its aim is to provide funding to promising investigators to encourage and promote quality research in urology and clinical oncology. The awards given are based on individual merit and availability of funds. An applicant must have attained a postgraduate degree or a doctoral degree...
Source: Kidney Cancer Association - October 30, 2017 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Request for Proposals (RFP)
Kidney Cancer Young Investigator Award (YIA)(PRWeb October 30, 2017)Read the full story at http://www.prweb.com/releases/2017/10/prweb14857468.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 30, 2017 Category: Pharmaceuticals Source Type: news

CDMRP:Transforming Healthcare through Innovative and Impactful Research
Kidney Cancer Research (KCRP) has been funded by the CDMRP for many years under various programs including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and, most recently, by the Peer Reviewed Cancer Research Program (PRCRP). From FY10 through FY16, the PRCRP invested over $9.8M in kidney cancer research. In FY17 the US Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program.10/28/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 28, 2017 Category: Urology & Nephrology Source Type: news

Request for Proposals (RFP): Kidney Cancer Young Investigator Award (YIA)
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017. The YIA is a one-year research grant totaling $50,000, which is paid in two equal installments to the awardee’s institution. Its aim is to provide funding to promising investigators to encourage and promote quality research in urology and clinical oncology. The awards given are based on individual merit and availability of funds. An applicant must have attained a postgraduate degree or a doctoral degree...
Source: Kidney Cancer Association - October 28, 2017 Category: Urology & Nephrology Source Type: news

UT Health San Antonio researchers define mechanism that causes kidney cancer to recur
(University of Texas Health Science Center at San Antonio) Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and US Department of Veterans Affairs have identified the molecular mechanism causing kidney cancer to resist drug treatment. The findings were published in the journal Nature Communications. They discovered NOX4, an enzyme in the cell's mitochondria, senses the Warburg effect (movement of adenosine triphosphate's energy production from inside to outside the mitochondria), and switches on to initiate drug resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Study indicates arsenic can cause cancer decades after exposure ends
(Oxford University Press USA) A new paper published in the Journal of the National Cancer Institute shows that arsenic in drinking water may have one of the longest dormancy periods of any carcinogen. By tracking the mortality rates of people exposed to arsenic-contaminated drinking water in a region in Chile, the researchers provide evidence of increases in lung, bladder, and kidney cancer even 40 years after high arsenic exposures ended. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Kidney cancer breakthrough: THIS could be why more men than women suffer from symptoms
KIDNEY cancer is more prevalent in men, and researchers believe male sex hormones could be the reason why. (Source: Daily Express - Health)
Source: Daily Express - Health - October 17, 2017 Category: Consumer Health News Source Type: news

Study Reveals Complex Biology, Gender Differences, in Kidney Cancer
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Study reveals complex biology, gender differences, in kidney cancer
(University of Rochester Medical Center) A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. The study shows that in renal cell carcinoma androgen signaling can either stimulate or suppress tumor cells' movement and invasion to different locations in the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2017 Category: Cancer & Oncology Source Type: news

Important support services at the fingertips of cancer patients
“Today, more than 15 million people in the United States are living with cancer and that number is expected to grow as emerging science and better therapies are likely to increase the number of patients living with cancer as we strive for a cure..."10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 10, 2017 Category: Urology & Nephrology Source Type: news

Novel programs to put important support services at the fingertips of cancer patients
“Today, more than 15 million people in the United States are living with cancer and that number is expected to grow as emerging science and better therapies are likely to increase the number of patients living with cancer as we strive for a cure..."10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 7, 2017 Category: Urology & Nephrology Source Type: news

Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence
Adjuvant treatment of renal-cell carcinoma (RCC) after nephrectomy with sunitinib has produced no increase in overall survival, but the treatment results in less distant disease recurrence and a higher rate of disease-free survival, according to the latest data from the S-TRAC study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Wanted: 1 million people to study genes, habits and health
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact...10/05/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 5, 2017 Category: Urology & Nephrology Source Type: news

Dana Farber/Harvard Kidney Cancer Symposium
10th Annual Dana Farber/Harvard Cancer Center Kidney Cancer Symposium 09/28/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 28, 2017 Category: Urology & Nephrology Source Type: news

Will You Answer This Question? It Will Help To Determine The Future Of Patient Education
We're seeking your input on the planning of a large patient education meeting that would span two days and include presentations from leading experts from the major institutions...10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 24, 2017 Category: Urology & Nephrology Source Type: news

Southern Cancer Center is Global Leader in Kidney Cancer Clinical Trial
Mobile, Ala. (September 19, 2017) - Southern Cancer Center (SCC), a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients. (Source: McKesson News)
Source: McKesson News - September 19, 2017 Category: Information Technology Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Department of Defense Kidney Cancer Research Program
The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).09/30...
Source: Kidney Cancer Association - September 14, 2017 Category: Urology & Nephrology Source Type: news

Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.09/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news

Kidney Cancer Guidelines
NCCN's Caitlyn Donnelly (left), Katy Winckworth-Prejsnar (center), and KCA's Paula Bowen (right) display Kidney Cancer Patient Guidelines® in French and German at the 2017 ESMO meeting in Madrid. Chinese and English translations are also available both online and in hardcopy from NCCN and KCA.09/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news

Bristol's drug cocktail cuts kidney cancer death risk 37 percent
MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival
It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."09/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 10, 2017 Category: Urology & Nephrology Source Type: news

BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers stops kidney cancer drug test after early success
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers stop kidney cancer drug tests after early success
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers kidney cancer drug meets early success, study stopped
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial early, despite having reported mixed results on other main goals earlier. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers kidney cancer drug meets main goal of late-stage trial
(Reuters) - Bristol-Myers Squibb Co said on Thursday its combination therapy of its two top drugs to treat a type of kidney cancer met one of the main goals of a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Kidney cancer symptoms: Seven signs YOU could be suffering with the disease
KIDNEY cancer is one of the most common types of cancer in the UK - usually affect people in their 60s and 70s. (Source: Daily Express - Health)
Source: Daily Express - Health - September 1, 2017 Category: Consumer Health News Source Type: news

European Commission licences EUSA ’s advanced RCC treatment fotivda
Jazz Pharmaceuticals subsidiary EUSA Pharma ’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Translocation Renal Cell Carcinoma: An Update
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Advice For Newly Diagnosed Patients From Mike Lawing
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world ’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.08/26/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Cancer drug turns BLACK cancer patient WHITE due to side effect
(Natural News) Can a drug for cancer be racist? That might be the rallying call of “antifa” terrorists, should they find out about what’s happening to Paula Edwards, a 54-year-old black woman from Loughborough in England. Edwards has reportedly been taking a drug for terminal kidney cancer known as Votrient (pazopanib), manufactured by Novartis, that... (Source: NaturalNews.com)
Source: NaturalNews.com - August 28, 2017 Category: Consumer Health News Source Type: news

OncoBreak: Bad News via Microscope; Risky B Vitamins; End of Kidney Cancer Trend?
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 24, 2017 Category: American Health Source Type: news

Longer Telomeres Linked to Renal-cell Carcinoma Risk Longer Telomeres Linked to Renal-cell Carcinoma Risk
Genetic variants that predispose individuals to longer telomere length appear to be associated with an increased risk of renal-cell carcinoma (RCC), according to results from a genome-wide association studies (GWAS) database analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Kidney Cancer Renal Pelvis and Ureter
Kidney Cancer: Renal Pelvis and Ureter (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 22, 2017 Category: General Medicine Source Type: news

Geriatric Consults Remain Rare in Kidney Cancer Care
Although use of medical co - management and rehabilitation services increasing (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 21, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Nephrology, Nursing, Oncology, Radiology, Surgery, Urology, Journal, Source Type: news

Exelixis Submits sNDA for Kidney Cancer Drug
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).08/20/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

California kidney cancer shows declining incidence
The research study, published online in the peer-reviewed journal Kidney Cancer, is important because it is the first report to demonstrate that the rising rate of kidney cancer seen in the U.S. over the past two decades may have ended.08/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

'Junk food' may increase cancer risk in 'healthy weight' women
"Women who eat junk food such as burgers or pizza are increasing their risk of cancer even if they're not overweight, new research has warned," reports the Daily Mail. The story is based on research from the US looking at the diet of postmenopausal women in the 1990s and then tracking the development of a variety of cancers over about 15 years. "Junk food" is often defined as food that is rich in calories (energy dense food) but low in nutrients. Having a diet high in energy dense foods, such as biscuits, chocolate and pizza was found to increase the risk of cancer in these women, specifically in those ...
Source: NHS News Feed - August 18, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Black cancer patient slowly turning white because of drug
Paula Edwards, 54, from Loughborough, was diagnosed with terminal kidney cancer in 2012 and was initially given 12 months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2017 Category: Consumer Health News Source Type: news

Black cancer patient is slowly turning white
Paula Edwards, 54, from Loughborough, was diagnosed with terminal kidney cancer in 2012 and was initially given 12 months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2017 Category: Consumer Health News Source Type: news

Study of California kidney cancer shows declining incidence, end of a trend
(University of California - Davis Health System) Study of kidney cancer incidence in California over 25 years is the first report to demonstrate that the rising rate of kidney cancer seen in the US over the past two decades may have ended. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2017 Category: Cancer & Oncology Source Type: news